BACKGROUND: Epidemiologic studies examining associations between carotenoid intakes and risk of breast cancer by estrogen receptor (ER) and progesterone receptor (PR) status are limited. OBJECTIVE: We investigated these associations in a pooled analysis of 18 cohort studies. DESIGN: Of 1,028,438 participants followed for a maximum follow-up of 26 y across studies, 33,380 incident invasive breast cancers were identified. Study-specific RRs and 95% CIs were estimated by using Cox proportional hazards regression and then pooled by using a random-effects model. RESULTS: α-Carotene, β-carotene, and lutein/zeaxanthin intakes were inversely associated with the risk of ER-negative (ER-) breast cancer (pooled multivariable RRs of the comparison between the highest and lowest quintiles): α-carotene (0.87; 95% CI: 0.78, 0.97), β-carotene (0.84; 95% CI: 0.77, 0.93), and lutein/zeaxanthin (0.87; 95% CI: 0.79, 0.95). These variables were not inversely associated with the risk of ER-positive (ER+) breast cancer (pooled multivariable RRs for the same comparison): α-carotene (1.04; 95% CI: 0.99, 1.09), β-carotene (1.04; 95% CI: 0.98, 1.10), and lutein/zeaxanthin (1.00; 95% CI: 0.93, 1.07). Although the pooled RRs for quintile 5 for β-cryptoxanthin were not significant, inverse trends were observed for ER- and ER+ breast cancer (P-trend ≤ 0.05). Nonsignificant associations were observed for lycopene intake. The associations were largely not appreciably modified by several breast cancer risk factors. Nonsignificant associations were observed for PR-positive and PR-negative breast cancer. CONCLUSIONS: Intakes of α-carotene, β-carotene, and lutein/zeaxanthin were inversely associated with risk of ER-, but not ER+, breast cancer. However, the results need to be interpreted with caution because it is unclear whether the observed association is real or due to other constituents in the same food sources.
BACKGROUND: Epidemiologic studies examining associations between carotenoid intakes and risk of breast cancer by estrogen receptor (ER) and progesterone receptor (PR) status are limited. OBJECTIVE: We investigated these associations in a pooled analysis of 18 cohort studies. DESIGN: Of 1,028,438 participants followed for a maximum follow-up of 26 y across studies, 33,380 incident invasive breast cancers were identified. Study-specific RRs and 95% CIs were estimated by using Cox proportional hazards regression and then pooled by using a random-effects model. RESULTS: α-Carotene, β-carotene, and lutein/zeaxanthin intakes were inversely associated with the risk of ER-negative (ER-) breast cancer (pooled multivariable RRs of the comparison between the highest and lowest quintiles): α-carotene (0.87; 95% CI: 0.78, 0.97), β-carotene (0.84; 95% CI: 0.77, 0.93), and lutein/zeaxanthin (0.87; 95% CI: 0.79, 0.95). These variables were not inversely associated with the risk of ER-positive (ER+) breast cancer (pooled multivariable RRs for the same comparison): α-carotene (1.04; 95% CI: 0.99, 1.09), β-carotene (1.04; 95% CI: 0.98, 1.10), and lutein/zeaxanthin (1.00; 95% CI: 0.93, 1.07). Although the pooled RRs for quintile 5 for β-cryptoxanthin were not significant, inverse trends were observed for ER- and ER+ breast cancer (P-trend ≤ 0.05). Nonsignificant associations were observed for lycopene intake. The associations were largely not appreciably modified by several breast cancer risk factors. Nonsignificant associations were observed for PR-positive and PR-negative breast cancer. CONCLUSIONS: Intakes of α-carotene, β-carotene, and lutein/zeaxanthin were inversely associated with risk of ER-, but not ER+, breast cancer. However, the results need to be interpreted with caution because it is unclear whether the observed association is real or due to other constituents in the same food sources.
Authors: W C Leung; S Hessel; C Méplan; J Flint; V Oberhauser; F Tourniaire; J E Hesketh; J von Lintig; G Lietz Journal: FASEB J Date: 2008-12-22 Impact factor: 5.191
Authors: Keren Hirsch; Andrea Atzmon; Michael Danilenko; Joseph Levy; Yoav Sharoni Journal: Breast Cancer Res Treat Date: 2006-10-19 Impact factor: 4.872
Authors: Pamela L Horn-Ross; K J Hoggatt; Dee W West; Melissa R Krone; Susan L Stewart; Hoda Anton; Culver Leslie Bernstei; Dennis Deapen; David Peel; Richard Pinder; Peggy Reynolds; Ronald K Ross; William Wright; Al Ziogas Journal: Cancer Causes Control Date: 2002-06 Impact factor: 2.506
Authors: Marian L Neuhouser; Ruth E Patterson; Mark D Thornquist; Gilbert S Omenn; Irena B King; Gary E Goodman Journal: Cancer Epidemiol Biomarkers Prev Date: 2003-04 Impact factor: 4.254
Authors: A Heather Eliassen; Xiaomei Liao; Bernard Rosner; Rulla M Tamimi; Shelley S Tworoger; Susan E Hankinson Journal: Am J Clin Nutr Date: 2015-04-15 Impact factor: 7.045
Authors: Kelly A Hirko; Walter C Willett; Susan E Hankinson; Bernard A Rosner; Andrew H Beck; Rulla M Tamimi; A Heather Eliassen Journal: Breast Cancer Res Treat Date: 2016-02-12 Impact factor: 4.872
Authors: Julia S Sisti; Sara Lindström; Peter Kraft; Rulla M Tamimi; Bernard A Rosner; Tianying Wu; Walter C Willett; A Heather Eliassen Journal: Breast Cancer Res Treat Date: 2015-04-28 Impact factor: 4.872
Authors: A Heather Eliassen; Sara J Hendrickson; Louise A Brinton; Julie E Buring; Hannia Campos; Qi Dai; Joanne F Dorgan; Adrian A Franke; Yu-tang Gao; Marc T Goodman; Göran Hallmans; Kathy J Helzlsouer; Judy Hoffman-Bolton; Kerstin Hultén; Howard D Sesso; Anne L Sowell; Rulla M Tamimi; Paolo Toniolo; Lynne R Wilkens; Anna Winkvist; Anne Zeleniuch-Jacquotte; Wei Zheng; Susan E Hankinson Journal: J Natl Cancer Inst Date: 2012-12-06 Impact factor: 13.506
Authors: Teresa T Fung; Stephanie E Chiuve; Walter C Willett; Susan E Hankinson; Frank B Hu; Michelle D Holmes Journal: Breast Cancer Res Treat Date: 2013-03-27 Impact factor: 4.872
Authors: William F Anderson; Philip S Rosenberg; Lucia Petito; Hormuzd A Katki; Bent Ejlertsen; Marianne Ewertz; Birgitte B Rasmussen; Maj-Britt Jensen; Niels Kroman Journal: Int J Cancer Date: 2013-06-13 Impact factor: 7.396
Authors: Seungyoun Jung; Donna Spiegelman; Laura Baglietto; Leslie Bernstein; Deborah A Boggs; Piet A van den Brandt; Julie E Buring; James R Cerhan; Mia M Gaudet; Graham G Giles; Gary Goodman; Niclas Hakansson; Susan E Hankinson; Kathy Helzlsouer; Pamela L Horn-Ross; Manami Inoue; Vittorio Krogh; Marie Lof; Marjorie L McCullough; Anthony B Miller; Marian L Neuhouser; Julie R Palmer; Yikyung Park; Kim Robien; Thomas E Rohan; Stephanie Scarmo; Catherine Schairer; Leo J Schouten; James M Shikany; Sabina Sieri; Schoichiro Tsugane; Kala Visvanathan; Elisabete Weiderpass; Walter C Willett; Alicja Wolk; Anne Zeleniuch-Jacquotte; Shumin M Zhang; Xuehong Zhang; Regina G Ziegler; Stephanie A Smith-Warner Journal: J Natl Cancer Inst Date: 2013-01-24 Impact factor: 13.506